Translate
Job title
Consultant medical oncologist
Contact details
PA/secretary tel: 020 7794 0500 ext 32325
or 020 7830 2396
Melanoma email:
rf.
Lung email: p.
Related services
Biography
Dr Pender is a consultant medical oncologist who undertook translational and laboratory research at the Institute of Cancer Research from 2013-2016 leading to a PhD.
Her awards include the Innovative Protocol Award at the 2016 ESMO Workshop on methods in clinical cancer research, and the Novartis Oncology Young Canadian Investigator Award.
GMC number
6154923
• Shokoohi A, Al-Hashami Z, Moore S, Pender A, Wong SK, Wang Y, Leung B, Wu J, Ho C. Effect of targeted therapy and immunotherapy on advanced non small-cell lung cancer outcomes in the real world. Cancer Med. 2022 Jan;11(1):86-93. doi: 10.1002/cam4.4427. Epub 2021 Nov 16. PMID: 34786889; PMCID: PMC8704182.
• Chavda A, Pender A, Cresswell M. (2021) Imaging-Guided Palliative Procedures: Tendon and Bursa Injection. Chapter In: Interventional Radiology in Palliative Care, Eds: Munk P.L., Babu S.B. Medical Radiology. Springer, Cham. https://doi.org/10.1007/978-3-030-65463-4_7
• Pender A*, Titmuss E*, Pleasance E, Fan KY, Pearson H, Brown SD, Grisdale CJ, Topham JT, Yaoqing Shen Y, Bonakdar M, Taylor GA, Williamson LM, Mungall K, Chuah E, Mungall AJ, Moore RA, Lavoie J-M, Yip S, Lim H, Renouf DJ, Sun S, Holt RA, Jones SJM, Marra MA, and Laskin J Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors Clin Cancer Res 2021 Jan ;27(1):202-212 *Joint first authors
• Pender A, Hughesman C, Law E, Kristanti A, McNeil K, Wong S, Tucker T, Bosdet I, Young S, Laskin J, Karsan A, Yip S, Ho C EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes Transl Lung Cancer Res 2020 Aug;9(4):1084-1092. doi: 10.21037/tlcr-19-581.PMID?3295348
• Naso JR, Wang G, Pender A, Wong SK, Zhu J, Ho C, Ionescu DN, Zhou C Intratumoural Heterogeneity in PD-L1 Immunoreactivity is Associated with Variation in Non-Small Cell Lung Carcinoma Histotype Histopathology 2019 Aug 27. doi: 10.1111/his.13983
• Ho C, Lefresne S, Liberman M, McGuire A, Palma D, Pender A, Snow S, Tremblay A, Myers R Lung Cancer in Canada J Thorac Oncol 2019; 14 (7): 1128-33
• Pender A, Jones RL, Pollack S Optimising cancer vaccine design in sarcoma Cancers 2018; 11 (1) pii: E1 doi: 10.3390/cancers11010001
• Pender A, Davis EJ, Chauhan D, Messiou C, Al-Muderis O, Thway K, Fisher C, Zaidi S, Miah A, Judson I, van der Graaf W, Keedy VL, Benson C, Jones RL Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol 2018 20;35(10):131 doi: 10.1007/s12032-018-1193-5
Dr Pender's research interests include circulating tumour DNA in lung cancer, immunotherapy and clinical trials of new therapies in melanoma and lung cancer.